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SUMMARY 
Arthritis, osteoporosis, and other bone diseases and defects are common medical issues 
worldwide. By utilizing ceramic biomaterials as bone substitutes to treat these diseases, bone 
regeneration can be promoted, and toxicity from the substitute material can be limited. Calcium 
phosphate (CaP) ceramics have become popular as bone substitutes because of their 
biocompatibility and similarity in composition to natural bone. The purpose of this research was 
to investigate the physical properties and biological responses of CaP-based bone substitutes, 
doped with metal ions. Some metal ions are present in natural bone in small amounts, and recent 
studies show that they affect the biological responses of CaPs significantly. Dopants such as 
magnesium (Mg), strontium (Sr), silicon (Si), and iron (Fe) alter the phase composition, 
mechanical properties, and osteogenesis and angiogenesis properties of CaPs, depending on their 
concentration and method of addition. In the present study, the effects of cobalt (Co) and copper 
(Cu) on the physical and biological properties of two main CaP materials, brushite cement (BrC) 
and tricalcium phosphate (TCP), were investigated. Different concentrations of dopants in forms 
of oxide and/or chloride were selected, and their effects on phase composition, sintering 
behavior, density, setting time, compressive strength, and in vitro interaction with osteosarcoma 
and osteoblast cells were studied. Different techniques of sample preparation, challenges during 
cement preparation and compact sample pressing, sintering, and methods of dopant addition are 
discussed.  
The presence of Cu in TCP was found to increase thermal stability of the material and decrease 
the impact of sintering temperature on porosity. In addition, Cu caused a reduction in expression 
of inflammatory gene markers by human osteoblast cells and an increased expression at early 
time points of osteoinductive markers. 
The addition of Cu and Co to brushite cement caused an increase in thermal stability of the 
material, and the addition of Cu caused a significant increase in setting time. Small dopant 
amounts of Co caused a decrease in setting time, but higher amounts caused an increase. In 
addition, Cu dopant in small amounts resulted in an increase of compressive strength. Both Cu 
and Co led to a decrease in expression of inflammatory gene markers by osteoblast and 
osteosarcoma cells, respectively, and Cu also caused an increase in osteoinductive marker 
expression. These results indicate that Cu and Co have a positive impact on the physical, 
mechanical, and biological properties of CaP biomaterials. 
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CHAPTER 1   INTRODUCTION 
1.1 Biology of Bone 
The dry bone mass of a healthy adult comprises 15–20% of his/her total body weight while the 
skeletal system overall constitutes 30–40% of an adult’s weight [1]. This system is integral in 
structurally supporting the body and protecting the vital organs, and it also enables motion 
through connection with the muscles. What is often referred to as “bone” is more formally 
known as osseous tissue. The two types of bone tissue present in the body and depicted in Figure 
1 [2] are cancellous and cortical, which are mainly identified by their densities. Cortical bone is 
much denser than cancellous bone; cancellous bone is porous, flexible, and much weaker than 
cortical. At the microstructure level, cortical bone functions through the Haversian, or osteon, 
system. In this system, the blood flow is conducted through “Haversian canals,” which are in the 
middle of each osteon and are surrounded by a cylindrical lamellae tissue layer made from 
collagen fibers [2]. These single Haversian systems are reported to have tensile strengths of 
around 17 ksi, compressive strengths around 16 ksi, bending strength around 56 ksi, and 
torsional strength around 29 ksi [3–6]. In contrast, cancellous bone (see Table 1) is composed of 
trabecula, which is bone tissue formed into a rod to enhance mechanical functionality. This 
structure allows cancellous bone to have a higher degree of porosity, mostly greater than 75%, 
while still maintaining a reasonable strength, depending of course on the age of the bone and 
region in the body [8,9]. 
 
 
Figure 1. Cortical bone vs. cancellous bone [7]. 
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Table 1. Properties of cancellous bone [8]. 
Mechanical Property 
No. of 
Samples Age Apparent Density (lb/in
3
) 
Young’s Modulus (Mpa) 142 67 ±15 0.00978 
Shear Modulus (Mpa) 42 Bovine – 
σy (MPa, tension) 52 65 ±14 0.01048 
σy (MPa, compression) 68 65 ±14 0.00978 ±0.00614 
σult (MPa, tension) 22 54 ±11 0.00686 ±0.00145 
σult (MPa, compression) 22 54 ±11 0.00614 ±0.00145 
 
Cortical bone is often found as the outside tissue surrounding the inner cancellous bone, though 
cancellous bone is also found on the end of longer bones such as the femur. Mechanical 
properties of the femur, tibia, and other bones are shown in Table 2. Cancellous bone is 
remodeled more often than cortical bone; this is a function of its higher metabolic activity 
compared to cortical bone, and it also means that it is often younger than cortical bone [2]. This 
remodeling process involves the resorption of old bone tissue and the formation of new bone 
tissue and occurs mainly as a function of the bone cells. Osteoblasts are the bone-forming cells 
but they are also involved in resorption, while osteoclasts only perform the resorption. When 
osteoblasts form new bone, it is initially uncalcified and known as osteoid bone.  
 
Table 2. Properties of human bone [10]. 
Human (20–39 years) Bone Femur Tibia Humerus Radius 
Ultimate Tensile Strength (Mpa) 124 ±1.1 174 ±1.2 125 ±0.8 152 ±1.4 
Ultimate Percent Elongation 1.41 1.50 1.43 1.50 
Modulus of Elasticity in Tension (Gpa) 17.60 18.40 17.50 18.90 
Ultimate Compressive Strength (Mpa) 107 ±4.3 
   
Ultimate Percentage Contraction 1.85 ±0.84 
   
Ultimate Shear Strength (Mpa) 54 ±0.6 
   
Torsional Modulus of Elasticity (Gpa) 3.20 
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Osteoblasts originate from mesenchymal stem cells (MSCs), which are multipotent cells that 
have the potential to differentiate into osteoblasts, adipocytes, chondrocytes, and myoblasts [11]. 
MSCs that differentiate to osteoblasts react to the runt-related transcription factor 2 (RUNX2) 
protein, and osteoblast differentiation, in turn, is regulated by various hormones as shown in 
Figure 2 [12,13]. Osteoblasts differentiate into bone lining cells known as osteocytes [14]. These 
osteocytes embed themselves in the bone matrix newly formed by osteoblasts and may also play 
a role in mechanical stress transduction and thus gene regulation, though this process is not yet 
well understood [15–17]. The continued differentiation of osteoblasts relies on osteoblast-
produced cytokines like insulin growth factor 1 (IGF-1) and bone morphogenetic proteins 
(BMPs) [11]. Collagen, which makes up a significant portion of the organic portion of the bone 
matrix, is produced by osteoblasts, as are noncollagenous proteins like osteocalcin and 
osteonectin [11].  
Another significant protein secreted by osteoblasts is osteoprotegerin (OPG), which is a decoy 
receptor for receptor activator of nuclear factor kappa-ß ligand (RANKL). This is significant 
because differentiation of osteoclasts relies on RANKL binding with receptor activator of 
nuclear factor κ ß (RANK) [19,20]. Thus, as OPG binds with RANKL instead, osteoclast 
differentiation is inhibited (Figure 3).  
 
 
Figure 2. Constant bone remodeling process facilitated by osteoclasts and osteoblasts [18]. 
 
Osteocyte  Osteoblast   Osteogenic cell Osteoclast 
(maintains  (forms bone matrix)  (stem cell)  (resorbs bone) 
bone tissue) 
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Figure 3. RANKL binding mechanism [21]. 
 
Compared to osteoblasts, osteoclasts are large, multinucleated cells whose main purpose is the 
resorption of bone. To resorb bone, osteoclasts attach to the surface of the bone and create a seal 
around the area to be resorbed. They then secrete hydrochloric acid, which dissolves the mineral, 
and the proteolytic enzyme cathepsin K, which breaks down the bone matrix [19,22]. As 
mentioned previously, the differentiation of osteoclasts is significantly regulated by the 
prevalence of OPG, RANKL, and RANK, where an overabundance of OPG can cause the 
resorption process to decrease, leading to increased bone mass and thus osteopetrosis, and 
conversely a lack of OPG can lead to excessive bone resorption and osteoporosis [23]. However, 
there are many other markers that indicate healthy bone formation, including alkaline 
phosphatase 1 (ALP-1), vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), 
interleukin-17 (IL-17), tumor necrosis factor-α (TNF-α), collagen type 1 α (COLA-1), 
osteocalcin (OCN), and hypoxia inducible factor 1-α (HIF-1α).  
1.2 Effective Markers in Bone Remodeling 
OPG and RANKL—As previously discussed, OPG is a decoy receptor for RANKL secreted by 
osteoblasts. It has been observed that with an upregulation of RANKL, OPG is downregulated 
and osteoporosis results [19]. However, when OPG is able to bind with RANKL, 
osteoclostogenesis is inhibited [24]. Studies have shown that OPG-deficient mice experience 
osteoporosis and loss of bone mass while OPG-transgenic mice experience osteopetrosis [25]. 
Interestingly, OPG has also been observed to inhibit calcification of large blood vessels [19]. 
RANKL is a member of the tumor necrosis factor (TNF) family, and its expression is affected by 
T cell activation [24]. It plays a major role in the formation and activation of osteoclast cells and 
also appears to play a role in rheumatoid arthritis joint breakdown [19].  
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ALP—ALP is an osteoblast-synthesized ectoenzyme that plays a role in bone calcification [26–
28]. Its exact role is not fully understood, but it is clearly linked to healthy bone. An increased 
expression of ALP is observed with osteoblast differentiation, and many studies suggest that 
early indication of cellular activity and differentiation can be gathered from the measured ALP 
expression [29]. In addition, mechanical force has been observed to increase ALP expression, 
and ALP expression is increased during fracture healing [28]. 
VEGF—This growth factor is expressed by osteoblasts, osteoclasts, and chondrocytes, and it 
stimulates and regulates their growth, differentiation, proliferation, and survival [30–32]. It also 
plays a large role in angiogenesis, or the growth of blood vessels, as well as in the ossification of 
bone [33,34]. Osteogenesis and angiogenesis are closely related and interdependent, and VEGF 
is one growth factor that bridges the gap between the two. VEGF is integral in endochondral 
ossification, which is one method by which bone is ossified [30]. VEGF has been found to 
stimulate osteoblast differentiation by as much as 70%, though low expression is observed at the 
beginning of osteoblast differentiation, and most expression of VEGF occurs during 
mineralization [35,36]. Several studies have shown that scaffolds incorporated with VEGF and 
slow-release mechanisms are therapeutic for bone healing [30,37]. However, excessive amounts 
of VEGF can also decrease bone healing [31]. 
IL-6—The presence of the proinflammatory cytokine IL-6 can stimulate bone formation by 
inducing osteoblast differentiation and can also inhibit the formation of osteoclasts [38,39]. It 
also enhances the formation of the extracellular matrix (ECM) and increases expression of ALP< 
OCN and other genes that are involved in calcification [39,40]. An increased presence of IL-6 
has been found in the joints of patients with osteoarthritis, and inhibited expression of IL-6 has 
been found to eliminate osteoarthritis in mice studies [38,41]. In addition, osteoblasts have seen 
protection from apoptosis because of TNF-α serum depletion by IL-6, though results are 
inconclusive [39]. 
IL-17—The IL-17 cytokine is proinflammatory and mostly originates from specialized T cells 
[42,43]. It is associated with inflammatory diseases like rheumatoid arthritis and is profuse in the 
sunovial fluid of such patients’ joints. Studies have shown IL-17 to stimulate ALP expression in 
MSCs and to have a positive effect on calcium and mineralized deposition of the ECM [44]. 
Reports also show that IL-17 promotes osteogenesis and osteoclastogenesis, though its role is 
still being defined [43,44]. IL-17 may have a stimulating effect on RANKL expression and also 
may promote osteogenic differentiation of MSCs [43,45]. 
TNF-α—The TNF-α cytokine is mainly secreted by macrophages and leads to the formation and 
activation of osteoclasts [46]. It is also linked to reduced osteoblast proliferation, and it has been 
found to limit the expression of differentiation markers of osteoblasts like OCN, COLA-1, and 
ALP. As such, TNF-α is associated with bone loss and excessive bone resorption and is 
associated with inflammatory bone diseases [46]. In rat calvaria models, the addition of TNF-α 
decreased the osteoblast proliferation to maturity and decreased osteoblast differentiation [47]. 
COLA-1—Collagen is abundantly produced by osteoblast cells, and COLA-1 is a gene that 
produces part of type 1 collagen, which is completed by the chain produced by COLA-2. Type 1 
collagen is fibril forming and is essential to the production of the ECM [48]. In addition, the 
COLA-1 gene has been linked to ALP production and the differentiation of osteoblast cells [48]. 
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OCN—Osteocalcin is secreted almost entirely by osteoblast cells and is one of the most prolific 
noncollagenous proteins found in bone [49,50]. Secretion of this protein is found mostly in 
mature osteoblast cells, and it acts to recruit osteoclasts and osteoblasts [51]. It also plays a role 
in signaling and is considered an indicator of bone formation [49–51]. OCN’s ability to bind with 
hydroxyapatite makes it an integral part in the mineralization of bone and the ECM, though some 
studies suggest that OCN does not play a role in bone mineralization [50–52]. OCN is also an 
indicator of bone metabolic activity [49].  
HIF-1α—In general, the activation of hypoxia inducible factors (HIFs) occurs in response to a 
reduction in oxygen, as the name suggests. HIF-1α specifically encodes the α subunit of HIF-1 
and activates the transcription of genes such as VEGF. As such, HIF-1α is a crucial link between 
angiogenesis and osteogenesis in skeletal and bone formation [53,54]. In addition, studies show 
that a lack of HIF-1α results in bones with a smaller diameter and a lack of vascularization, and 
that HIF-1α contributes to the protection of articular cartilage in certain cases [53,55].  
1.3 Need for Bone Substitute Materials 
Osteoporosis, arthritis, bone fracture, and other bone trauma are prevalent around the world and 
cause significant loss of productivity and decrease in quality of life. According to a 2017 Centers 
for Disease Control study, the 10-year probability of a hip fracture within the next 10 years for 
an individual aged 80 or older in the United States is 72% [56]. This fracture becomes more 
likely with osteoporosis because, as shown in Figure 4, the density of bone decreases. In 
addition, it is estimated that 16% of Americans suffer from arthritis, and 43% of those 
experience physical limitations due to the disease [57]. In 2013, arthritis cost $304 billion in 
wages lost and medical expenses incurred [58]. In addition, astronauts exposed to prolonged 
zero-gravity effects experience greater risk for osteoporosis and bone loss, especially in the spine 
or hip [59]. 
  
Figure 4. Imbalance of osteoclast and osteoblast activity leads to osteoporosis [60].  
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Established methods such as grafts (Figure 5) have been implemented in the medical community 
to alleviate the effects of bone loss. Autografts, which are tissue grafts from one place on a 
patient’s body to another, are by far the desired remedy, but this solution requires two surgeries 
and additional time under anesthesia for the afflicted individual, which increases the potential for 
additional damage. Allografts are tissue grafts from a donor to a patient and are another viable 
solution, but the patient’s body may reject the donated tissue. An allograft from a genetically 
identical donor is known as a synograft and is usually not rejected by the patient’s body, but this 
method of transplant still requires two surgeries. Transplanting tissue from a different species, 
known as a xenograft, is also utilized in the medical industry but, as with allografts, there is a 
potential for the body to reject the unknown tissue.  
As an alternative solution, much emphasis has been placed on biomaterials. In a general sense, a 
biomaterial is any synthetic or natural material that is used in the body, and can include metals, 
ceramics, polymers, and any combination of these. 
 
 
 
Figure 5. Types of grafts. 
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Heat-activated polymers are particularly intriguing as drug delivery systems and stents. For load-
bearing bone sections or joint replacement, metal biomaterials are a natural choice because they 
are strong and resistant to fatigue. However, metals are often toxic to the body and, as they 
remain in the body over time, tend to leach harmful ions into the body. This can cause significant 
health concerns, as observed with metal-on-metal hip prostheses that require a second surgery to 
remedy the issues [61]. In addition, these materials do not integrate with the surrounding bone, 
which can cause a phenomenon known as fibrous encapsulation (Figure 6) that occurs when the 
implant is surrounded by tissue but not integrated into the body [62]. This can cause the implant 
to loosen and eventually can necessitate a second surgery to repair the affected area. To counter 
this, the metal can be coated with a ceramic material. Ceramics have a composition like that of 
bone, which allows the body to more readily accept the implant and integrate it into the body. In 
addition, the coating can reduce the toxicity of the implant by eliminating the friction between 
the implant and the surrounding bone.  
However, in small bone defect sites in non-load-bearing areas, ceramics are often viewed as 
superior to metals. While these materials lack tensile and fracture strength, they have excellent 
compressive strength and, as previously mentioned, have similar composition to natural bone. 
There are numerous varieties of ceramics available and effective as implants, including 
bioglasses, metal oxides, and calcium phosphates.  
 
 
Figure 6. Fibrous encapsulation vs. stable fixation [63]. 
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Bioceramics are advantageous for use in biomaterial applications because they are often not 
toxic to the body. Some bioceramics, when implanted, can bond with the surrounding tissue and 
thus have superior fixation compared to metals or other inert ceramics. Some ceramics are inert 
and experience fibrous encapsulation, but this can be avoided if the material is porous. The 
porosity of many ceramics can be manipulated and optimized to ensure adequate pore size and 
distribution. Both macroporosity (>100 μm) and microporosity (<100 μm) are desired in 
biomaterials for biodegradability, fixation, and enhanced osteoconduction [64]. If a material has 
surface reactivity with the surrounding tissue, it will biologically fixate to the tissue and avoid 
detrimental fibrous encapsulation. Porosity plays a large role in accomplishing this and is 
necessary for the circulation of blood and new cells while also providing a mechanism for waste 
removal. Growth factors, BMPs, and other osteogenic factors also circulate through these 
interconnected pores and ultimately lead to enhanced osteoinduction. Mechanical strength is also 
regulated through pore size and interconnectedness. Thus, CaP biomaterial porosity is an integral 
consideration in designing scaffolds and implants. 
1.4 Calcium Phosphate Bone Substitutes 
CaP ceramics are well-suited for bone substitution applications, as their composition is similar 
to that of human bone. Bone is composed of 36 wt. % calcium and 17 wt. % phosphorous 
(Table 3), which allows the body to more readily accept these ceramic bone substitutes compared 
to other materials that the body is unfamiliar with and thus rejects [65]. In addition, because of 
the similarity of the material to bone, CaPs often elicits a biological response from the body and 
bonds are formed between the implant and the native bone tissue. This leads to greater 
integration and higher success levels of implants. CaPs are also resorbable, which means the 
implant dissolves as the bone tissue regenerates. The physiological reactions of the many types 
of CaPs are distinguishable by their calcium-to-phosphate (Ca/P) ratio, which can be used to 
determine the solubility product and thus the application of the material, as well as by their phase 
composition and crystallinity. CaPs with a small solubility product such as hydroxyapatite (HA) 
have a high Ca/P ratio and are useful for more permanent applications, as the substitute will 
dissolve slowly over many years [66]. In contrast, materials with high solubility products and 
low Ca/P ratios, such as monocalcium phosphate monohydrate (MCPM), dissolve quickly and 
are useful in short-term applications [66]. Tricalcium phosphate (TCP) and dicalcium phosphate 
dihydrate (DCPD), which is also known as brushite, are of specific interest in this research. TCP 
can be expressed in two different phases (Table 4) based on the temperature at which it is 
calcined: α-TCP, which forms at temperatures above 1250 °C, and ß-TCP, which forms at lower 
temperatures and is stable up to 1125 °C [67]. α-TCP has a solubility factor of 10-26 while ß-TCP 
has a solubility factor of 10
-29
, though both phases have a Ca/P ratio of 1.5 [66]. This difference 
in solubility products by a factor of 3 is significant and is a good example of how minor 
variations in Ca/P ratio can affect the solubility product. The Ca/P ratio of DCPD is 1.0, and it 
has a solubility factor of 10
-7
, which indicates a much higher rate of resorbability compared to 
TCP [66]. DCPD is often used as a cement because of its high solubility product. However, as 
ceramics, these materials have low tensile and fracture strengths, which makes them unsuitable 
substitutes in load-bearing areas, though they can be used in small defects that bear relatively 
small loads [68]. In addition, as the implants are resorbed, their mechanical strength will 
decrease because of the dissolution of the material.  
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Table 3. Composition of bone relative to mineral fraction or wet human bone (cobalt and copper) [69,70]. 
Wt. % Bone (%) 
Ca 36.6 
P 17.1 
CO2 4.8 
Na 1 
K 0.07 
Mg 0.6 
Sr 0.05 
Cl 0.1 
F 0.1 
 
 
Table 4. Calcium phosphate biomaterials [66]. 
Calcium Phosphate Abbreviation 
Chemical 
Formula 
Ca/P Molar 
Ratio 
Solubility 
Product 
Monocalcium phosphate  
monohydrate MCPM CaH4P2O8 0.5 7.2 × 10
-2 
Dicalcium phosphate dihydrate 
(brushite) DCPD CaHPO4  2H2O 1 2.5 × 10
-7 
α-tricalcium phosphate α-TCP α-Ca3(PO4)2 1.5 3.16 × 10
-26 
β-tricalcium phosphate β-TCP β-Ca3(PO4)2 1.5 1.25 × 10
-9 
Hydroxyapatite HA Ca5(PO4)3(OH) 1.67 1 × 10
-38 
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1.5 Osteoinductivity of Biomaterials 
To quantify the performance of these bone substitute materials, the osteoconductivity and 
osteoinductivity of the materials are observed, among other properties. Osteoconductivity, which 
is the ability of a material to act as a scaffold for new bone growth, is an inherent property of all 
CaPs. Osteoinductivity, which is the ability of a material to induce new bone formation without 
growth factors, is a property that CaPs without additives do not possess. In specific instances, 
some CaPs have exhibited osteoinductive properties, but the enhancement of the osteoinductive 
properties of CaPs remains a crucial topic in bone engineering [71]. Osteoinduction is vital 
because these CaP bone substitutes should contribute to the ultimate healing of the defect site. As 
previously mentioned, as the substitutes are resorbed, new bone formation should occur so that 
the defect site can return to complete functionality.  
Several methods for enhancing osteoinduction have been studied and reported, including using 
CaPs enhanced with trace amounts of metal ions or growth factors [68,72–74]. The use of 
growth factors to enhance osteoinductivity has been well documented, and many studies using 
bone morphogenetic proteins (BMPs), insulin-like growth factors (IGFs), MSCs, vascular 
endothelial growth factors (VEGFs), and others can be found [75–78]. These growth factors 
enhance cell proliferation and the expression of many proteins and indicators of bone growth 
such as collagen and osteocalcin. Likewise, there is a wealth of research and publications 
regarding incorporation of metal ions into CaPs to enhance osteoinductivity. Trace elements are 
found in small amounts within the body already, and they play vital roles in maintaining health. 
Iron’s presence in the blood, magnesium’s presence in tissue, and zinc’s cellular presence are 
just a few examples. By incorporating trace amounts of metal in CaP bone substitutes, the 
therapeutic effects of these metals can be harnessed. Of course, an excess of metal is toxic at the 
cellular level, and as such, in-depth studies must be conducted. Mg, Li, Fe, Si, Sr, Cu, Co, Zn, 
and many others are among the elements have been studied. Depending on the amount of trace 
element used, the type of CaP, the type of cell or implant location studied, and other factors, the 
biological response varies. Zn and Sr are often utilized or combined in cellular studies. They 
have been found to increase ALP expression and cell adherence in osteoblast cells cultured on 
doped BrC samples, as well as in pig trabecular bone [79]. Other studies have corroborated the 
positive effects of doping CaPs with Zn and Sr on bone formation and healing [76,80]. Mg has 
also been linked to OPG and RANKL levels and bone morphogenic protein 2 (BMP-2) 
expression [81–83]. Cell differentiation and proliferation have been enhanced with the 
incorporation of Li as a dopant in CaP materials, as has the ability of the cell structure to mature 
[84–86]. Si promotes expression of VEGF and ALP and also enhances matrix mineralization 
through collagen production [87–90]. In this current research, Cu and Co specifically were 
studied and were observed as dopants in both ß-TCP and BrC in various dopant amounts. 
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1.6 Trace Elements Used to Enhance Osteoinductivity 
Instances of both cupric (Cu
2+
) and cuprous (Cu
+
) copper can be found in the body; most copper 
intake comes from digested food, while about 10% comes from water [91]. A normal adult has 
between 18–45 µg of Cu per gram of dry weight located within the liver and about 6 mg of Cu in 
the blood [92]. Copper plays a strong role in Fe metabolism and is itself metabolized in the liver 
and absorbed mostly in the small intestine, where it is bound to albumin and transported in blood 
[91,93]. For the average adult, a lethal dose of Cu is between 10–20 grams, while general Cu 
toxicity can lead to liver cirrhosis. In cellular toxicity, the most popular theory states that cell 
death occurs because of the free ions of Cu forming reactive oxygen species (ROS) [91]. 
Regarding cellular presence, Cu has been linked to angiogenesis, or the growth of blood vessels, 
and to the expression of VEGF, which is a vital growth factor that is expressed during 
angiogenesis [94–96].  
Cobalt is another essential element that is well known in the composition of vitamin B12. The 
highest concentrations of Co are found in the liver and kidney, while it is absorbed from the 
gastrointestinal and pulmonary tracts [97]. The average adult has an intake between 5–45 µg of 
Co per day and has about 1.5 mg of Co stored in the body [97,98]. It has been reported that the 
main source of Co toxicity comes from essential macromolecules mistakenly binding to Co 
instead of the correct element. This causes the macromolecule to function improperly and is most 
common for macromolecules seeking Fe because of the similar radius of Fe and Co [99]. In 
clinical settings, the administration of Co was used for treatment of anemia in the 1940s, where 
18.5–37 mg Co per day was prescribed to patients. These patients did not show any significant 
signs of toxicity, but children given 3–4 mg of cobalt chloride per kg of body weight experienced 
goitrogenic effects until the dose was discontinued [98]. In addition, cardiomyopathy outbreaks 
were reported from those who ingested Co-infused beer, and neurological symptoms were 
experienced because of Co toxicity from metal-on-metal hip prostheses [97,100,101]. 
1.7 Fabrication of Bone Substitute Materials 
Fabrication methods of CaP bone substitute materials are diverse and depend extensively on their 
application and the desired properties. 3D printing of bioceramics offers the fabricator the ability 
to design scaffolds with specific pore size and overall shape and allows quick reproduction. In 
addition, growth factors and proteins can easily be incorporated into the scaffold. To incorporate 
these biological factors, however, low-temperature printing is needed, which poses a challenge 
[102]. The integration of polymers into the scaffold to enhance the mechanical properties and 
reduce material impurities has also been utilized in the form of particle leaching, thermally 
induced phase separation, electrospun scaffolds, and others [103,104]. The aforementioned 
methods allow for customizable pore size and enhanced interconnectivity of the materials. Other 
applications require injectability, for which cements are particularly well suited. Cements are 
created by mixing a solid and a liquid, after which their shape can be molded before the setting 
reaction completes and the cement is hardened. In addition, these cements inherently have 
microporosity, which enhances biointegration [105]. Early issues observed with the use of 
cements were poor binding properties, so additives such as polyethylene glycol (PEG) were 
necessary to eliminate such problems [106,107]. To fabricate, the powder and liquid are mixed, 
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poured into a mold, and allowed to set at high humidity. Other methods of powder preparation 
include uniaxial and isostatic pressing followed by sintering at high temperatures [108].  
1.8 Research Objectives 
Based on the literature review and previous research conducted, new areas of research were 
defined. The prevalence of CaPs used as biomaterials is evident, but much research and 
discovery are yet to be done before these ceramics can reach their potential for impacting the 
medical community.  
The biocompatibility, resorbability, mechanical properties, physical properties, and 
manufacturability exhibited by TCP and DCPD contributed to the decision to utilize these as the 
two materials investigated herein. Significant previous research has been done regarding these 
materials, and this research serves to extend that knowledge base.  
Cu has been identified as an essential trace element in living tissue, and previous studies have 
shown its effectiveness in stimulating angiogenesis and cell proliferation. The research lacks 
details regarding the effect of Cu on specific markers of osteoinductive genes, and lacks 
coverage of Cu additives in brushite cement and TCP samples. 
Likewise, the anti-inflammatory effects of Co additives to bioceramics have been documented, 
but Co as an additive to brushite as a scaffold for cell growth is relatively absent in literature, as 
are studies discussing the role of Co in cell proliferation. 
Thus, the research objectives of this study are: 
1. Quantify the physical, mechanical, and biological effects of doping TCP with Cu. 
TCP powder was synthesized by the solid-state method, and relative amounts of Cu were added 
prior to calcination at 1050 °C. The resulting powder was mixed with ethanol and ball-milled to 
break up the material into fine powder, and then dried in a furnace. Fine powder was formed into 
cylinder scaffolds by a die and uniaxial press and subsequently sintered. The crystal structure of 
the samples was studied by x-ray diffraction (XRD), and the surface morphology was observed 
by scanning electron microscopy (SEM). The density was tested by measuring volume, dry and 
wet weight of samples, and using Archimede’s method of calculation. For biological studies, the 
samples were sterilized and then seeded with osteoblast cells, which were harvested at various 
time points. Quantitative real-time polymerase chain reaction (qPCR) methods were used to 
quantify gene expression, and XTT assay was used to obtain cellular proliferation. 
2. Quantify the physical, mechanical, and biological effects of doping BrC with Cu and Co. 
Brushite powder was obtained by first synthesizing TCP powder and calcinating at 1050 °C. To 
obtain fine powder, the calcinated material was mixed with ethanol, ball-milled, and dried in a 
furnace. Half of the powder was kept coarse, and a mixture of fine TCP, coarse TCP, 
monocalcium phosphate monohydrate (MCPM), magnesium hydrogen phosphate trihydrate, 
sodium pyrophosphate dibasic, and magnesium sulphate was ground with a mortar and pestle to 
mix evenly. XRD was used to quantify crystal structure, and SEM illuminated the surface 
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morphology. Compression testing was conducted to obtain the compression strength, and a 
Gilmore needle was used to test setting time. The brushite powder was mixed with a 
polyethylene glycol (PEG)-water combination to form cement and then poured into a mold. 
Samples were allowed to set at 100% humidity for 1 hour, then submerged in phosphate-buffered 
saline (PBS) for 24 hours to complete setting reaction. Sterilized samples were seeded with 
osteoblast cells, and qPCR and XTT assay were used to obtain gene expression and cell 
proliferation. 
 
CHAPTER 2   COPPER-DOPED TCP 
2.1 Introduction 
While all CaPs are osteoconductive, many of them, including β-TCP, lack osteoinductivity [73]. 
Osteoinduction in CaPs including ß-TCP is often enhanced by incorporating growth factors and 
dopants [68,72,73]. The effects of bone morphogenic protein 2 (BMP-2) addition to gelatinous  
ß-TCP scaffolds were studied in vivo in the back subcutis of rats, and it was found that with 
increased percentage of BMP-2 incorporation into the scaffolds, increased alkaline phosphatase 
(ALP) and osteocalcin (OCN) activity was observed, and thus osteoinductivity was enhanced 
[75]. This study also found that the phase intensity of ß-TCP increased with increasing Co [109]. 
In another study, β-TCP doped with MgO, SrO, and SiO2 was substituted into distal femur 
cortical defect in rats, and histomorphology of the defects was performed 4, 8, 12, and 16 weeks 
post-implantation [110]. The physical properties of the samples were affected by the dopants, as 
the XRD results showed the β-to-α transition temperature increased as a result of MgO addition. 
Further, β-TCP doped with a combination of MgO and SrO was found to enhance bone 
formation and remodeling through high osseous activity [110]. Previously it was shown that 
osteoblast cells cultured in the presence of Li-doped β-TCP had increased cell adhesion and 
proliferation compared to pure TCP samples [84]. The stability of the Li-doped samples was also 
increased, as was the bulk density of the samples because of the decrease of lattice volume by 
substitution of Li ions into the Ca sites [84].  
Cu has been widely used in biomedical applications and is necessary for many physiological 
processes and for certain intracellular protein functions [111,112]. The average 70-kg adult male 
contains approximately 100 mg of Cu, with the highest concentration distributed within the liver, 
and Linder also reports an average of 1.11 µg/ml of Cu in both whole blood and in plasma [113]. 
Further, Cu-deficient anemia can result in skeletal deformities, and Cu deficiency is linked to 
defective tissue formation [114]. Cu deficiencies also affect the metabolism of other trace 
elements; for example, it increases the iron (Fe) concentration in the liver significantly [115]. In 
addition, Cu metabolism is affected by inflammation and infection [93]. Many studies have 
shown improved angiogenesis in Cu-substituted biomaterials while no adverse effect on cellular 
response was reported. Wu et al. found increased vascular endothelial growth factor (VEGF) and 
stabilized hypoxia-inducible factor 1-alpha (HIF-1α) expression in Cu-doped bioglass scaffolds, 
whereas no adverse effect on mesenchymal stem cell proliferation was found because of the 
presence of Cu [116]. Enhanced angiogenesis was also found in Cu-loaded dicalcium phosphate 
dihydrate (DCPD) scaffolds at 56- and 560-ng Cu loading when implanted into the peritoneal 
cavity of mice [95]. Ewald et al. showed that not only the angiogenic properties, but also the 
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osteoblastic proliferation and activity, were enhanced in DCPD when loaded with 5.65 and 0.56 
µg/cm
2
 Cu [117]. In this work, the experiments focused on elucidating the effects of different 
concentrations of Cu on the proliferation and differentiation of osteoblasts in ß-TCP. Markers of 
differentiation and inflammation including OPG, COLA-1, ALP-1, OCN, VEGF, IL-6, TNF-, 
and RANKL were investigated 
This study hypothesized that the addition of Cu to ß-TCP in trace amounts will alter osteoblast 
(OB) cell growth and gene expression, and sample phase composition and microstructure. To 
validate, corresponding amounts of CuO were added to TCP precursors, and samples were 
prepared by uniaxial press and sintering. OB cells were seeded and allowed to grow before 
harvesting and analysis by XTT and quantitative real-time polymerase reaction (qPCR). X-ray 
diffraction (XRD) and scanning electron microscopy (SEM) were also utilized to analyze the 
phase and microstructure of samples. 
2.2 Materials and Methods 
2.2.1 Sample Preparation 
Pure TCP powder was prepared by solid-state synthesis, explained in detail in reference [106]. 
Briefly, two moles calcium hydrogen phosphate anhydrous (CaHPO4, Alfa Aesar, >99.0%) and 
one mole calcium carbonate (CaCO3, Alfa Aesar, >98.0%) were ball-milled at a powder:milling 
media ratio of 1:4 for 2 hours and then calcined at 1050 °C for 24 hours in a muffle furnace. The 
calcined powder was naturally cooled to room temperature. Copper (II) oxide was added to 
CaHPO4 and CaCO3 precursors at 0.25, 0.5, and 1.0 wt. % concentrations to prepare the doped 
TCP, and the mixture was processed similar to undoped TCP. Hereinafter, these concentrations 
are referred to as Pure-TCP, 0.25 Cu-TCP, 0.5 Cu-TCP, and 1.0 Cu-TCP. The powder was then 
crushed and mixed with ethanol for 6 hours at a powder:ethanol ratio:milling media ratio of 
1:1.5:5. The mixture was then dried at 65 °C for 3–4 days, until all the ethanol was evaporated. 
Powder was poured into a 13-mm-diameter die set, which was held at 25.5 kN for 2 minutes by a 
uniaxial press. Samples were then transferred to a porous zirconia substrate and sintered at 1150 
°C for 2 hours using a muffle furnace, followed by cooling to room temperature. 
One issue that was discovered during the sample preparation was that the surface of all the 
samples was shearing off after the die was compressed with the uniaxial press. This problem was 
mitigated by preparing two samples at the same time in the die. The first sample always sheared 
and broke apart, but the second sample had no surface cracks or blemishes. This was due to the 
length of the pin in the die set. According to the die manufacturer, the correct range of material 
powder must be added to the die in order to produce desirable samples, like those in Figure 7. In 
order to obtain the desired sample dimensions, the two-sample method described above was 
used.  
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Figure 7. Cu-doped TCP samples on scaffolds for sintering. 
 
2.2.2 Phase Composition, Surface Morphology, and Density 
The phase composition of the samples was analyzed with a Rigaku D/MAX diffractometer using 
CuKα radiation, equipped with an Ni filter at a step size of 0.04° and a count time of 1.5 seconds 
per step. The relative α-TCP phase intensity compared to the ß-TCP phase intensity was 
calculated by: 
 
                    
                            
 Eq. 1 
After applying a thin-layer coating of Pd/Au, microstructure of the top surface of the samples 
was performed using a field emission scanning electron microscope (FESEM, Hitachi model 
S4500). Relative bulk and apparent densities were measured by specimen dimension and 
Archimedes’ method. Samples were submerged in boiling water for 2 minutes to ensure all 
trapped air was removed from internal pores and then immediately submerged in room-
temperature water to obtain the wet weight. The relative bulk density of the samples was 
calculated as mass per volume of each sample divided by the nominal density of TCP, which is 
3.07 g/cm
3
. The percentage obtained subtracted from 100% gave the total porosity. Apparent 
density was calculated as the dry weight divided by the difference between dry and wet weight, 
which, when divided by nominal density, gives relative apparent density. Apparent density 
subtracted from 100% gives the percentage of closed pores, and by subtracting this percentage 
from the total porosity percentage, the open porosity can be obtained.  
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2.2.3 Cell Culture 
The human osteoblast cell line hFOB 1.19 (hFOB; see Figure 8) was purchased from ATCC 
(Manassas, VA) and cultured in complete growth medium (DMEM supplemented with 10% fetal 
bovine serum (FBS) and antibiotic/antimycotic). Before use, disks were sterilized using an 
autoclave. Disks were placed in 24 well plates (one disk per well), and hFOB cells were seeded 
on top of each disk, followed by culturing in the presence of additional cell culture media. All 
experiments were conducted at 34 
o
C in the presence of CO2. 
2.2.4 Assessment of Cell Growth Using XTT Assay 
Cells were suspended in complete growth medium at a concentration of 50 × 10
3
 cells/20 μl. TCP 
disks were placed in triplicate wells of a 24-well plate. Twenty μl of concentrated cells were 
added to TCP disks and allowed to adhere to the top of each disk, then 400 μl of complete 
growth media were added to each well. Cells were cultured at 34 ºC in the presence of 5% CO2 
and media was replenished every 3–4 days. After 5 or 10 days, media was carefully removed 
from the wells and the disks were washed gently with 1 ml of Dulbecco’s Phosphate-Buffered 
Saline (DPBS) (ThermoFisher Scientific, Waltham, MA). TCP disks were then removed and 
placed into a new 24-well plate, followed by the addition of 400 μl of DPBS and 100 μl of XTT 
working solution (Trevegin, Gaithersburg, MD), and incubated at 34 ºC for 3 hours, then 
analyzed on an Epoch plate reader (Biotek, Winooski, VT; see Figure 9). 
 
 
 
 
Figure 8. Osteoblast cells used for cell 
culture. 
 Figure 9. Epoch plate reader for XTT. 
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2.2.5 Assessment of Gene Expression 
For gene expression studies, 2 × 10
6
 cells/20 μl were seeded on top of each TCP disk in triplicate 
wells of 24-well plates, followed by addition of 400 μl cell culture medium. After 1 or 5 days 
incubation, media was removed and the disks were washed gently with 1 ml DPBS. Samples 
were placed into new 24-well plates and the cells were immediately lysed using 1 ml TRIzol 
reagent (ThermoFisher Scientific), and the total RNA was isolated following manufacturer’s 
protocol as previously published [109,118]. Reverse transcription reactions were performed 
using Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega, Madison, WI). 
Quantitative real-time PCR (qPCR) was conducted using the ViiA7 real-time PCR instrument 
(Life Technologies, Grand Island, NY). Gene expression was calculated by subtracting the 
threshold cycle (CT) for the housekeeping gene (GAPDH) from the gene of interest, and relative 
gene expression was compared to cells grown on pure TCP disks. The following primers were 
used in this study:  
GAPDH, 5’-CTCGACTTCAACAGCGACA- 3’ (forward) and  
5’-GTAGCCAAATTCGTTGTCATACC-3’ (reverse);  
OPG, 5’-GTCTTTGGTCTCCTGCTAACTC-3’ (forward) and  
5’-CCTCACACAGGGTAACATCTATTC-3’ (reverse);  
COLA1, 5’-CGATGGATTCCAGTTCGAGTATG-3’ (forward) and  
5’-CTTGCAGTGGTAGGTGATGTT-3’ (reverse);  
ALP-1, 5’-CCTACCAGCTCATGCATAACA-3’ (forward) and  
5’-GGCTTTCTCGTCACTCTCATAC-3’ (reverse);  
OCN, 5’-CAGGCGCTACCTGTATCAAT-3’ (forward) and  
5’-CGATGTGGTCAGCCAACT-3’ (reverse);  
VEGF, 5’-GATGAGCTTCCTACAGCACAA-3’ (forward) and  
5’-CTTTCCCTTTCCTCGAACTGAT-3’ (reverse);  
IL-6, 5’-TCCAAAGATGTAGCCGCCC-3’ (forward) and  
5’-CAGTGCCTCTTTGCTGCTTTC-3’ (reverse);  
TNF-, 5’-CCAGGGACCTCTCTCTAATCA-3’ (forward) and  
5’-TCAGCTTGAGGGTTTGCTAC-3’ (reverse); and 
RANKL, 5’-AGCACATCAGAGCAGAGAAAG-3’ (forward) and  
5’-TGTCGGTGGCATTAATAGTGAG-3’ (reverse).  
 
2.2.6 Statistical Analysis 
A one-way analysis of variance (ANOVA) was used to determine the statistical significance 
between groups. Statistical significance is denoted as * (p<0.05), ** (p<0.01), *** (p<0.001), 
and **** (p<0.0001). Statistical analysis was performed using GraphPad Prism software (La 
Jolla, CA). 
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2.3 Results 
2.3.1 Phase Analysis 
The relative amount of α-TCP for samples sintered at 1150 °C is listed in Table 5. Figure 10 
shows XRD patterns of ß-TCP powder after calcination, initial calcination, and after sintering at 
1050°C and 1150 °C for pure-TCP, 0.25 Cu-TCP, 0.5 Cu-TCP, and 1.0 Cu-TCP samples. ß-TCP 
phase was the only phase present in the structure of all samples after calcination and sintering at 
1050 °C. An increase in sintering temperature to 1150 °C resulted in the formation of α-TCP in 
pure-TCP, 0.25 Cu-TCP, and 0.5 Cu-TCP, whereas no secondary phase was observed in 1.0  
Cu-TCP.  
 
Figure 10. XRD of TCP powder and samples sintered at 1050, 1150, and 1250 °C. 
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Table 5. α-TCP phase intensity percentages. 
 α  Intensity (%) 
Pure-TCP 17.46 
0.25 Cu-TCP 4.92 
0.5 Cu-TCP 2.76 
1.0 Cu-TCP 0 
 
 
2.3.2 Density 
The total porosity and open porosity of samples sintered at 1050 ºC and 1150 ºC were measured 
and are shown in Figure 11. In general, the porosity decreased with higher sintering temperature 
at all concentrations, as shown in Table 6, except at 0.25 Cu-TCP, where the total porosity of 
1150 ºC samples was greater than 1050 ºC samples and the open porosity was nearly equivalent. 
At 1050 ºC, among doped samples, 0.5 Cu-TCP had the greatest total and open porosity with no 
difference in porosities of 0.25 Cu-TCP and 1.0 Cu-TCP. 0.25 Cu-TCP had the greatest porosity 
at 1150 ºC, with total porosity decreasing linearly with dopant amount. The open porosity of pure 
TCP was significantly less at 1150 °C and slightly less at 0.5 Cu-TCP and 1.0 Cu-TCP. 
 
Table 6. Comparison of open and total porosities at different sintering temperatures. 
 
1050 °C Total 
Porosity 
1150 °C Total 
Porosity % Change 
Pure TCP 33.74 ±0.51 31.26 ±0.61 7.35 
0.25 Cu-TCP 32.45 ±0.14 37.45 ±0.39 -15.41 
0.5 Cu-TCP 33.87 ±0.66 33.35 ±0.44 1.54 
1.0 Cu-TCP 31.87 ±0.16 31.89 ±0.67 -0.06 
 
1050 °C Open 
Porosity 
1150 °C Open 
Porosity % Change 
Pure TCP 29.6 ±0.95 27.25 ±0.67 7.94 
0.25 Cu-TCP 29.84 ±0.03 30.3 ±0.98 -1.54 
0.5 Cu-TCP 31.29 ±0.67 28.31 ±0.50 9.52 
1.0 Cu-TCP 29.29 ±0.32 28.97 ±0.64 1.09 
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Figure 11. Total and open porosity of TCP samples sintered at 1050 and 1150 °C. 
 
 
2.3.3 Assessment of Cell Proliferation 
XTT assay was used to determine proliferation of osteoblast cells on pure and Cu-TCP samples 
after 5 and 10 days of culture. OB cells were able to proliferate on pure-TCP samples as 
evidenced by increased relative proliferation from day 5 to day 10 (p<0.0001) and as shown in 
Figure 12. No difference was found in cell proliferation between pure-TCP and 0.25 Cu-TCP 
samples at both 5 and 10 days. However, the addition of higher concentrations of Cu resulted in 
a significant decrease in cell proliferation at both time points in a dose-dependent manner.  
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Figure 12. Proliferation of osteoblast cells after 5 and 10 days incubation. 
 
2.3.4 Assessment of Cell Differentiation and Inflammation 
In this study inflammatory gene expression by qPCR was evaluated after 1 and 5 days of sample 
seeding. The addition of Cu to TCP samples did not affect IL-6 expression at day 1 (Figure 13). 
Furthermore, although IL-6 expression increased in pure TCP samples from day 1 to day 5, IL-6 
expression was significantly reduced after 5 days for all Cu-doped samples in a dose-dependent 
manner. Similar to IL-6, there was significant reduction in TNF- levels in Cu-doped samples at 
day 1 and day 5. However, there was an increase in IL-17 expression, particularly in samples 
doped with a high-percent Cu (1%) at 1 and 5 days. 
The expression of several differentiation markers in FOB grown on TCP samples was also 
examined. It was found that expression of osteoprotegerin (OPG) did not change in the presence 
of any Cu concentration at an early time point (day 1). However, at day 5, OPG expression was 
significantly reduced at 1% Cu-TCP compared to pure TCP, despite increased expression of 
OPG on pure TCP samples at day 5 compared to day 1. The expression of osteocalcin (OCN) 
was not affected by the presence of Cu on TCP samples at earlier and later kinetics. Similarly, 
the expression of ALP-1, although initially decreased in the presence of 0.25 and 0.5% Cu on 
TCP, at 1% Cu, showed no difference, and at later kinetics, ALP-1 expression decreased but was 
not affected by Cu. This is in contrast to vascular endothelial growth factor (VEGF), collagen 
type 1 α (COLA-1), and receptor activator of nuclear factor kappa-B ligand (RANKL), where 
cells grown on 1% Cu-TCP had significantly increased expression at an early time point. 
However, the presence of Cu did not alter expression at later kinetics.   
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Figure 13. Gene marker expression of osteoblast cells after 1 and 5 days incubation. 
 
2.4 Discussion 
Calcium phosphates such as ß-TCP are a viable option for use as bone substitution materials 
because of their compositional similarity to bone, as well as many other features [68,119]. 
Though CaPs have limited osteoinductivity, this can be enhanced with the addition of trace 
elements such as Co, Zn, Si, and Cu. In this study, ß-TCP scaffolds were synthesized via the 
solid-state method and sintering, and the osteoinductivity and angiogenesis of OB cells, when 
cultured on pure ß-TCP scaffolds compared to Cu-doped ß-TCP, were examined. The effect of 
adding Cu to the physical properties of ß-TCP was also studied.  
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Prior to sintering all samples, two samples at each concentration were sintered at 1050 and 1150 
°C. XRD analysis was performed on each sample so that the phases present could be identified. 
Samples sintered at 1150 °C showed slight occurrences of α-TCP with the greatest intensities of  
β-TCP phases, whereas the samples sintered at 1050 °C showed only occurrences of β-TCP. 
Based on these findings, 1150 °C was the chosen sintering temperature for the remainder of the 
samples. The α-TCP transition generally occurs around 1125 °C [67], which is why there are  
α-TCP phases present in the 1150 °C samples. The 1050 °C sintering shows no presence of  
α-TCP, which is expected since the α-TCP transition occurs around 1125 °C.  
At high sintering temperatures, trace amounts of Cu were found deposited on the inside of the 
furnace that was utilized, as shown in Figure 14. This was visibly observed as pink streaks on the 
heating elements, and pink dots were also noted on the pure TCP samples. The contaminated 
samples were discarded, and crucibles were utilized to cover all samples to prevent further 
contamination. 
Increased levels of α-TCP result in a decreased dissolution rate compared to β-TCP, which can 
be seen by the solubility products and calcium-to-phosphate ratios of both calcium phosphates. 
The solubility product of calcium phosphates increases as the Ca/P ratio decreases. However, the 
calcium-to-phosphate ratio of both α- and β-TCP is 1.50 [120]. The solubility products of these 
calcium phosphates, however, differ by a factor of 3, with α-TCP having a higher solubility 
product than β-TCP [66]. Because of the increasing presence of α-TCP with increasing sintering 
temperature, it can be concluded that the dissolution rate will increase with increasing sintering 
temperature and that the stability of the samples therefore decreases with increasing sintering 
temperature. This same trend was recently observed in lithium-doped TCP and resulted in the 
decrease of compressive strength at higher sintering temperature [84]. Because of the relatively 
low α-TCP intensity compared with β-TCP found at 1150 °C, this temperature was chosen as the 
sintering temperature. The β- to α-TCP transition temperature has been documented as 1125 °C 
[67], so by sintering at 1150 °C and observing the small amounts of α phase, one can be certain 
that 1150 °C is a high enough temperature to complete the β-TCP reactions without having 
excessive occurrence of the α phase. 
 
 
Figure 14. Cu deposition on furnace heating elements.  
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The results of this study show that the addition of Cu
2+
 stabilizes the β-TCP crystal structure at 
1150 °C, where β-TCP to α-TCP phase transformation is expected [67]. Cu2+ incorporation 
decreases the α-TCP phase in a dose-dependent manner from 17.5 in pure TCP to 4.5, 2.8, and 0 
when 0.25, 0.5, and 1.0 wt. % of dopant is added, respectively. Because of the similar valence of 
Ca
2+
 and Cu
2+
, the copper ion substitutes the Ca sites in the TCP structure [121]. However, the 
ionic radius of Cu
2+
 is much smaller than Ca
2+
 (0.73 Å and 0.99 Å, respectively) and replacement 
of Ca with Cu causes the structural shrinkage, which eventually stabilizes the β-TCP structure. 
This data is in accordance with previous data that found that Ca
2+
 substitution with smaller Li
+
 
and Fe
3+
 reduces the α-TCP occurrence [84,122]. Studying the α-TCP formation is crucial as it 
increases the solubility product by a factor of 3, so faster dissolution is expected [3].    
The decrease in porosity that was observed with higher sintering temperature is expected because 
at higher temperatures the particles fuse together and there is higher density as a result. This also 
accounts for the decrease in open porosity for most Cu concentrations at higher temperatures. 
High temperatures (around 1000–1200 °C) are used to synthesize copper phosphates from CuO, 
so this may also affect the density [123]. The decrease in open porosity from 1050 to 1150 °C 
was significant for pure TCP samples but was much less so for the 0.25 and 1.0 Cu-TCP 
samples, which suggests that Cu addition decreases the effect of increasing sintering temperature 
on porosity. The same trend is apparent in total porosity as well, with the total porosity 
decreasing by almost 2.5% for pure TCP but only changing by 0.5 and 0.01% for 0.5 and 1.0  
Cu-TCP, respectively. Thus, it is evident that Cu addition contributes to thermal stability in this 
TCP. 
Copper is considered an essential trace element for humans and, because of the role that Cu plays 
in Cu-binding proteins, Cu deficiencies have been linked to cardiomyopathy, anemia, and many 
other serious health issues [111,114]. On the contrary, Cu excess has been linked to cirrhosis and 
decreased liver function, and excess Cu consumption has been shown to cause intestinal cramps 
and nausea [114]. On a cellular level, Cu toxicity is often credited to the creation of reactive 
oxygen species (ROS) by Cu ions, which ultimately leads to the breakdown of DNA strands 
[91]. However, in sufficiently small amounts, Cu has been reported to increase VEGF secretion 
in a variety of cell types and dopant concentrations [95,116,124]. Likewise, Cu has been 
observed to increase expression of osteogenic genes such as ALP, OCN, and OPN, though the 
results of the study by Schamel et al. show similar results between non-doped and doped samples 
[116,125,126]. In this study, the VEGF expression upregulated at early time points with the 
presence of Cu in a dose-dependent manner; however, at a later time point, the trend did not 
continue. This may be due to Cu toxicity and decreased cellular proliferation at 0.5 and 1.0  
Cu-TCP, resulting in fewer cells and thus less VEGF expression. Furthermore, the increase at 
earlier time points may be sufficient to induce a biological effect and sustained levels may no 
longer be needed. With up to 0.25 Cu-TCP, at both 5 and 10 days, no significant difference in 
cell proliferation was observed compared to pure TCP. However, at 0.5 Cu-TCP, relative cellular 
proliferation decreased, and at 1.0 Cu-TCP, significantly less cells were present at both time 
points compared to pure TCP. This indicates that 0.25 wt. % Cu addition is near the maximum 
amount of Cu that can be safely utilized as a dopant without negatively affecting cell 
proliferation.  
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Varied results were observed for osteoinductive gene expression of ALP and OCN, as there was 
no difference in the expression of OCN at earlier kinetics between the four samples, but there 
was an initial decrease in ALP expression in cells grown on 0.25 and 0.5 Cu-TCP and no change 
at 1.0 Cu-TCP compared to pure TCP. Perhaps the lack of effect on OCN is due to its abundance 
as a noncollagenous skeletal-derived protein [127]. This study found that ALP expression was 
initially higher at earlier kinetics and reduced at later kinetics (see Figure 3). This is consistent 
with the expression of ALP during bone development, where it is highly expressed during early 
bone development and expression is reduced during later development [128]. Both ALP and 
OCN are indicators of osteoblast differentiation, and OCN is known to be produced after 
maturation of the osteoblasts while ALP is an early indicator [50,129]. The observed increase in 
expression of OCN at the second time point in this study corroborates this data. At early time 
points, increasing the dopant amount resulted in an increase of COLA-1 expression, but at later 
kinetics the expression was similar for all concentrations and reduced compared to the Pure-TCP 
sample at early kinetics. Since ALP is an early indicator of osteoblast differentiation and  
COLA-1 is expressed prior to ALP, this trend is expected. OPG, as a decoy RANKL receptor, 
also enhances differentiation, and the absence of OPG has been linked to decreased bone mass in 
mice [24,130].  
This study found that at later kinetics, OPG expression was significantly increased with 0.25  
Cu-TCP compared to pure TCP. When RANKL binds with OPG instead of RANK, 
osteoclastogenesis is prevented, thus leading to enhanced bone formation [24]. IL-6 and TNF-α 
are both inflammatory genes and both were downregulated with Cu dopant in this study. IL-6 
promotes osteoarthritis and also leads to the upregulation of Ank, Anx-5, and Pit-1, which are all 
genes that lead to calcification [40]. Likewise, increasing TNF-α leads to decreasing ALP 
expression, decreasing osteoblast differentiation and upregulation of osteoclasts [46,47]. Finally, 
an increase in IL-17 expression at early and later kinetics was found. IL-17 was found to play a 
pro-osteogenic role in mesenchymal stem cells (MSCs), therefore the induction of IL-17 
expression may play an osteogenic role [44]. Thus, this study found that Cu dopants contribute to 
the formation of bone and can cause therapeutic inflammation inhibition. 
2.5 Conclusion 
The effects of Cu addition to TCP scaffolds on phase composition and physical and biological 
properties were reported in this study. Relative amounts of α-TCP phase intensity were found to 
significantly decrease with increasing amounts of Cu dopant. In addition, increasing sintering 
temperature had less of an effect on the open porosity of samples with higher Cu addition. 
Biologically, Cu dopant increased osteogenic markers and decreased the expression of 
proinflammatory markers. 
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CHAPTER 3   COPPER- AND COBALT-DOPED BRC 
3.1 Introduction 
Dicalcium phosphate dihydrate (DCPD) is one type of CaP that is commonly used because of its 
relatively high solubility factor of 2.5·10
-7
, which makes it highly resorbable. As a cement, it has 
high injectability and moldability, and DCPD has increased osteoinductivity compared to other 
CaPs, which leads to improved bone remodeling [66,131]. The osteoinductivity of DCPD is, 
however, still relatively low, so many methods have been used to enhance this property, 
including the incorporation of growth factors and ionic substitution [76,132]. This study 
evaluated the effects of doping brushite cement (BrC), a precipitate of DCPD, with Cu and Co. 
Copper (Cu) is an essential trace element in the body, helping the body to handle oxidative stress 
and defend against antioxidants [133]. As mentioned previously, the osteoinductive properties of 
BrC are limited, and methods have been explored to enhance these properties. Gene markers 
such as VEGF, ALP, OCN, OPG, and others are good indicators of bone growth, and the 
maximization of their expression is desired. Growth factors can enhance these markers, as can 
metal dopants, which were utilized in the present study. Co has been found to increase VEGF 
expression when added to hydroxyapatite scaffolds, and Fe increased ALP expression when 
added to ß-TCP [122,134]. The physical properties of calcium phosphates are also altered by the 
addition of metal ions; the study by Vahabzadeh et al. showed an increase in compressive 
strength and density with the addition of trace amounts of Li [84]. Another study by Bose et al. 
showed a significant decrease in compressive strength with the addition of Mg, Sr, and Si, and 
showed the effects on grain size with the addition of these dopants [110]. Cu as a dopant in 
various calcium phosphate biomaterials has been well documented as integral in blood vessel 
formation, and angiogenesis-related gene expression, such as VEGF, has been shown to increase 
with Cu stimulation [94,135–137]. Wu et al. showed that copper-doped mesoporous bioactive 
glass stimulated alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN) 
expression in human bone marrow stromal cells in a dose-dependent manner [116]. In another 
study, ALP activity of MC3T3-E1 mouse preosteoblast cells also increased up to 0.8 wt. % Cu 
addition in silicate bioactive glass [138]. However, Li et al. directly treated human umbilical vein 
endothelial cells (HUVEC) with CuSO4 and found that the expression of VEGF was not affected 
by Cu stimulation [139]. Li et al. also demonstrated Cu cytotoxicity at levels above 200 μmol/L 
[139]. Another study showed an increase in human mesenchymal stem cell proliferation up to 0.1 
mM Cu addition to Ti-64 plates, and no cytotoxicity up to 0.5 mM Cu addition [140].  
Recently, cobalt (Co) has been considered for use in different CaP systems [134,141,142]. Co is 
present in bone, dentine, and enamel with maximum concentration of 1 ppm [65] and is part of 
vitamin B12. Vitamin B12 (also known as cobalamin) plays an important role in DNA synthesis 
and neurological function, and its deﬁciency is associated with hematologic disorders as well as 
neuropsychiatric disorders [143]. Reported ﬁndings show the effective role of Co2+ in stabilizing 
the hypoxia inducible factor-1α (HIF-1α) and in inducing the angiogenesis [144]. Although 
hypoxia (low oxygen levels, 3% O2) is important in development and wound healing, 
dysregulated hypoxia plays an important role in several diseases such as cancer, and heart and 
lung disease [145]. In fact, tumor hypoxia is one of the most common conditions encountered  
in the tumor microenvironment and activates HIF-1α, which leads to the activation of a 
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transcriptional program that allows cells to adapt to this hypoxic environment and drives 
tumorigenesis [145]. Furthermore, a role for hypoxia in promoting inﬂammatory gene expression 
has been described, where it induces expression of interleukin 6 (IL-6), a cytokine that promotes 
tumorigenesis [145–147]. Among the different osteosarcoma cell lines, MG-63 is a suitable 
candidate to study the effects of different compositions and biomolecules on proliferation and 
differentiation of malignant bone cells, in vitro [148,149]. Therefore, this study examined the 
effects of Co concentration on short-term proliferation and expression of HIF-1α in the MG-63 
cell line under normoxic and hypoxic conditions.  
This study hypothesized that the addition of Cu and Co, in various concentrations, to BrC will 
alter the microstructure, phase composition, compressive strength, setting time, osteoblast and 
MG-63 osteosarcoma cell growth (under normoxic and hypoxic conditions), and gene 
expression. To validate this hypothesis, appropriate amounts of Cu and Co were added to TCP 
precursors, and DCPD cement samples were produced. These samples were evaluated by x-ray 
diffraction (XRD) and scanning electron microscopy (SEM) to characterize the phase 
composition and microstructure. Setting time was determined using a Gillmore needle, and 
compressive strength was evaluated. To determine the biological impact of Cu addition, 
quantitative real-time polymerase chain reaction (qPCR) and XTT (2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) techniques were utilized. 
3.2 Materials and Methods 
3.2.1 Powder Preparation 
To process the TCP powder, solid-state synthesis was used as explained in reference [106]. In 
brief, two moles of calcium hydrogen phosphate (CaHPO4, Alfa Aesar, >98.0%) and one mole of 
calcium carbonate (CaCO3, Alfa Aesar, >99.0%) were ball-milled for 2 hours at a powder:  
milling media ratio of 1:4. The mixture was then calcined for 24 hours at 1050 °C in a muffle 
furnace and cooled naturally to room temperature. The 0.25, 0.5, and 1.0 wt. % copper- or 
cobalt-doped tricalcium phosphate was prepared by adding proper amounts of copper oxide or 
cobalt oxide to the TCP precursors and then processed identically to undoped TCP (Figure 15). 
The (Ca+Cu or Co)/P molar ratio was kept at 1.5 during the entire process for the different 
concentrations of Cu and Co. 
Following calcination, half of the TCP was kept as coarse powder, and the other half was made 
into fine powder through mixing with ethanol and milling media for 6 hours at a powder: 
ethanol: milling media ratio of 1:1.5:5 and then drying at 65 °C for 3–4 days. 
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Figure 15. Doped TCP powders in crucibles after calcination. 
 
3.2.2 Cement Preparation 
To prepare cement powder, fine TCP, coarse TCP, and calcium phosphate monobasic 
monohydrate (MCPM, Ca(H2PO4)2·H2O, Sigma-Aldrich) were mixed by mortar and pestle at a 
ratio explained in reference [76]. Three grams of this powder were mixed consistently with 900 
μl of a polyethylene glycol (PEG, 2 wt. % in nanopure water) solution for 30 seconds and poured 
into a 7-mm-diameter mold. The mold was covered and incubated at 37 °C and 100% humidity 
for 1 hour. Samples were removed from the mold and kept in a phosphate-buffered saline (PBS) 
solution for 24 hours to complete the setting reaction.  
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3.2.3 Phase Composition and Surface Morphology 
The phase composition of the samples was analyzed by x-ray diffraction with a Rigaku D/MAX 
diffractometer using CuKα radiation, a step size of 0.04º, a count of 1.5 seconds per step, and an 
Ni filter. Calcined ß-TCP and BrC powders were analyzed, and the relative DCPD phase 
intensity compared to ß-TCP phase intensity was calculated for the brushite cement by: 
 
                      
                               
 Eq. 2 
The surface microstructure of the samples was captured by a field emission scanning electron 
microscope (FESEM, Hitachi model S4500) after a thin layer of Pd/Au was applied to the top 
surface.  
3.2.4 Setting Time 
Gillmore needles were used to measure the initial and final setting times. The cement was 
prepared as described above and then poured into the mold. The 0.83-in.-diameter 0.25-lb. 
needle was used to determine the initial setting time, and the 0.042-in.-diameter 1-lb. needle was 
used to determine the final setting time. Time was recorded from the moment when the cement 
was poured into the mold until the time when the corresponding needle ceased to indent the 
surface of the cement. 
3.2.5 Compressive Strength 
Compressive strength was measured with a 10-kN load cell. The sample was mounted in the 
center of the fixture and compressed until failure was sustained. The maximum force applied was 
recorded, and the compressive strength was calculated from this value and the area of the 
samples. 
3.2.6 Cell Culture 
The human osteoblast cell line hFOB 1.19 (hFOB) was purchased from ATCC (Manassas, VA) 
and maintained in complete growth medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and antibiotic/antimycotic. The MG-63 osteosarcoma cell line was purchased from 
ATCC and maintained in Eagle’s minimum essential medium (EMEM) supplemented with 10% 
heat-inactivated FBS and antibiotic/antimycotic. Disk samples were sterilized with 100% ethanol 
for 6 hours and dried under sterilized conditions (Figure 16) prior to use. Disks were then placed 
in 48-well plates (one disk per well) and seeded with hFOB cells for the Cu study and MG-63 
cells for the Co study on top of each disk, followed by the addition of cell culture media. All 
experiments were conducted in the presence of CO2 at 34 ºC for the hFOB and 37 °C for the 
MG-63. 
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Figure 16. Sterile cell culture hood located in department of biology. 
 
3.2.7 Assessment of Cell Growth Using XTT Assay 
Cells were suspended in complete growth medium at a concentration of 25 × 10
3
 cells/20 μl. BrC 
disks were placed in triplicate wells of a 48-well plate. Twenty μl of concentrated cells were 
added to BrC disks and allowed to adhere to the top of each disk, then 400 μl of complete growth 
media were added to each well. Cells were cultured at 34 ºC in the presence of 5% CO2, and 
media was replenished every 3–4 days for the Cu study. For the Co study, cells were incubated 
under normoxic (21% O2) or hypoxic (1% O2) conditions. After 1, 3, 5, or 7 days, media was 
carefully removed from the wells and the disks were washed gently with 1 ml DPBS 
(ThermoFisher Scientific, Waltham, MA). BrC disks were then removed and placed into a new 
48-well plate followed by the addition of 400 μl of DPBS and 100 μl of XTT working solution 
(Trevegin, Gaithersburg, MD) and incubated at 37 ºC for 3 hours, and then analyzed on an Epoch 
plate reader (Biotek, Winooski, VT). 
3.2.8 Assessment of Gene Expression 
For gene expression studies, 2 × 10
6
 cells/20 μl were seeded on top of each BrC disk in triplicate 
wells of 48-well plates, followed by the addition of 400 μl of cell culture medium (Figure 17). 
For the Co study, the cells were then incubated under normoxic (21% O2) or hypoxic (1% O2) 
conditions, whereas all conditions were normoxic for the Cu study. After 1-, 3-, 5-, or 7-day 
incubation, media was removed and the disks were washed gently with 1 ml DPBS. Samples 
were placed into new 48-well plates and the cells were immediately lysed using 1 ml TRIzol 
reagent (ThermoFisher Scientific), and the total RNA was isolated following manufacturer’s 
protocol as previously published [109,118]. Reverse transcription reactions were performed 
using Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega, Madison, WI). 
Quantitative real-time PCR (qPCR) was conducted using the ViiA7 real-time PCR instrument  
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(Life Technologies, Grand Island, NY). Gene expression was calculated by subtracting the 
threshold cycle (CT) for the housekeeping gene (GAPDH) from the gene of interest, and the 
relative gene expression was compared to cells grown on pure BrC disks. The following primers 
were used in this study:  
GAPDH, 5’-CTCGACTTCAACAGCGACA- 3’ (forward) and  
5’-GTAGCCAAATTCGTTGTCATACC-3’ (reverse);  
OPG, 5’-GTCTTTGGTCTCCTGCTAACTC-3’ (forward) and  
5’-CCTCACACAGGGTAACATCTATTC-3’ (reverse);  
COLA1, 5’-CGATGGATTCCAGTTCGAGTATG-3’ (forward) and  
5’-CTTGCAGTGGTAGGTGATGTT-3’ (reverse);  
ALP-1, 5’-CCTACCAGCTCATGCATAACA-3’ (forward) and  
5’-GGCTTTCTCGTCACTCTCATAC-3’ (reverse);  
OCN, 5’-CAGGCGCTACCTGTATCAAT-3’ (forward) and  
5’-CGATGTGGTCAGCCAACT-3’ (reverse);  
VEGF, 5’-GATGAGCTTCCTACAGCACAA-3’ (forward) and  
5’-CTTTCCCTTTCCTCGAACTGAT-3’ (reverse);  
IL-6, 5’-TCCAAAGATGTAGCCGCCC-3’ (forward) and  
5’-CAGTGCCTCTTTGCTGCTTTC-3’ (reverse);  
TNF-, 5’-CCAGGGACCTCTCTCTAATCA-3’ (forward) and  
5’-TCAGCTTGAGGGTTTGCTAC-3’ (reverse); and  
RANKL, 5’-AGCACATCAGAGCAGAGAAAG-3’ (forward) and  
5’-TGTCGGTGGCATTAATAGTGAG-3’ (reverse).  
For expression of HIF-1α and glioma-associated oncogene family zinc ﬁnger 2 (GLI2) relative to 
the expression of the housekeeping gene, GAPDH, the following primers were used:  
b-actin, 5¢-CTCGACTTCAACAGCGACA-3¢ (forward) and  
5-GTAGCCAAATTCGTTG TCATACC-3¢ (reverse);  
GLI2, 5¢-CTCCGAGAAGCAAGAAGCCA-3¢ (forward) and  
5-GATGCTGCGGCACTCCTT-3¢ (reverse);  
HIF-1α, 5 ¢-AACATAAAGT CTGCAACATGGAAG-3¢ (forward) and  
5¢-TTTGATGGGTGAGGAATGGG-3¢ (reverse). 
3.2.9 Statistical Analysis 
A one-way analysis of variance (ANOVA) was used to determine statistical significance between 
groups. Statistical significance is denoted as * (p<0.05), ** (p<0.01), *** (p<0.001), and **** 
(p<0.0001). Statistical analysis was performed by GraphPad Prism software (La Jolla, CA). 
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Figure 17. Brushite cement samples for qPCR. 
 
3.3 Results 
3.3.1 Phase Analysis 
3.3.1.1 Cu-BrC Phase Analysis 
The XRD data shows peaks from ß-TCP and DCPD, indicating formation of both phases as 
expected. Table 7 lists the measured intensity of the 100% peaks of DCPD and ß-TCP (JCPDS 
09-0077, 100% intensity at 21º, and JCPDS 09-0169, 100% intensity at 31.1º, respectively). The 
intensity of the DCPD phase significantly decreased with all Cu addition, with a less notable 
fluctuation in ß-TCP intensity as shown in Figure 18 and Figure 19. Comparing ß-TCP phase 
intensity to DCPD, there is a bell curve in the doped Cu data of DCPD that is inverted for  
ß-TCP. The relative DCPD phase intensity (calculated by Eq. 2) also decreased with Cu dopant. 
Table 7. Copper DCPD and ß-TCP phase intensity. 
 Pure-BrC 0.25 Cu-BrC 0.5 Cu-BrC 1.0 Cu-BrC 
DCPD Phase Intensity (a.u.) 1459 455 721 414 
ß-TCP Phase Intensity (a.u.) 1605 2043 1317 2119 
Relative % DCPD 47.6 18.2 35.4 16.3 
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Figure 18. Copper DCPD and ß-TCP phase intensity. 
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Figure 19. Copper TCP and BrC XRD graphs.  
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3.3.1.2 Co-BrC Phase Analysis 
Processed TCP in the current study was used as the precursor to fabricate the BrCs. As a result, 
phase analysis of TCP powders containing different concentrations of Co was necessary. XRD 
spectra of different TCP powders, calcined at 1050 °C, is presented in Figure 20. The results 
show that the ß-TCP (JCPDS No. 09-0169) was the only phase in pure and doped samples. No 
other phase including Co was found in the TCP samples. 
 
Figure 20. Cobalt TCP and BrC XRD graphs. 
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3.3.2 Surface Morphology 
SEM microstructure of pure and Co-BrC samples shows the presence of granular TCP along 
with needle/plate-like DCPD throughout the fracture surface of the specimen in Figure 21 [106]. 
This data is in line with the results from XRD that showed the presence of both phases in all 
samples.  
 
Figure 21. Cobalt BrC SEM images. 
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3.3.3 Setting Time 
3.3.3.1 Cu-BrC Setting Time 
Figure 22 shows that increasing Cu content causes an increase in both initial and final setting 
times. The most significant increase in setting time was observed between 0.5 and 1.0  
Cu-BrC. The initial setting time of 0.5 Cu-BrC was just over 7.5 minutes, whereas the initial 
setting time of 1.0 Cu-BrC was nearly double that. This is especially significant compared to the 
difference between 0.25 and 0.5 Cu-BrC, which was only about 1 minute, though the initial 
setting time of pure Cu-BrC was nearly half that of 0.25 Cu-BrC. This same general trend was 
observed in final setting times as well, with a final setting time of 1.0 Cu-BrC nearly 3 times that 
of 0.5 Cu-BrC. The difference between pure Cu-BrC and 0.25 Cu-BrC was slightly less 
compared to the initial setting time, however. 
3.3.3.2 Co-BrC Setting Time 
The setting time of BrC doped with Co (see Figure 23) increased with increasing amounts of Co, 
but a slight decrease in setting time was observed between pure BrC and 0.25 Co-BrC. The 
setting time of 0.5 Co-BrC and pure BrC was nearly the same for both initial and final setting 
times. A significant decrease in setting time was observed between 0.5 and 1.0 Co-BrC for both 
initial and final setting times. 
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Figure 22. Copper BrC initial and final setting times. 
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Figure 23. Cobalt BrC initial and final setting times. 
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3.3.4 Compressive Strength 
A clear bell curve is shown in Figure 24 from the results of compressive strength testing. The 
highest values of compressive strength occurred with 0.25 Cu-BrC, at which compressive 
strength of 6.3 MPa was recorded, while values for pure Cu-BrC and 0.5 Cu-BrC were nearly 
identical at 2.9 MPa and 3.3 MPa, respectively. The addition of 1.0 Cu-BrC significantly 
decreased compressive strength to 0.5 MPa. 
 
 
Figure 24. Copper BrC compressive strength. 
 
3.3.5 XTT Assay 
XTT assay was conducted to determine cell proliferation when cultured in the presence of pure, 
Cu-doped, and Co-doped BrC samples. The relative increase in osteoblast proliferation on pure 
BrC samples from day 3 to day 7 in Figure 25a suggests that OB cells were able to proliferate. 
The addition of Cu at all concentrations did decrease proliferation in a dose-dependent manner, 
though cells were able to proliferate as evidenced by the increase in relative proliferation 
between day 3 and day 7 for all Cu concentrations. Results in Figure 25b show that although 
there was a modest (20%) increase in MG-63 cell growth on pure BrC under hypoxia compared 
with normoxia, this increase did not reach statistical signiﬁcance (Figure 25a). Furthermore, the 
presence of Co at different concentrations did not affect MG-63 cell growth on BrC under 
normoxic or hypoxic conditions. 
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Figure 25. Relative osteoblast and MG-63 osteosarcoma cell proliferation. 
 
3.3.6 Gene Expression 
3.3.6.1 Cu-BrC Gene Expression 
Gene expression by the osteoblast cells was determined by the qPCR technique, and results are 
shown in Figure 26. Cells were harvested after 1-, 3-, and 7-day time points, and interleukin 6 
(IL-6), tumor necrosis factor α (TNF-α), interleukin 17 (IL-17), osteoprotegerin (OPG), receptor 
activator of nuclear factor kappa-Β ligand (RANKL), alkaline phosphatase 1 (ALP-1), vascular 
endothelial growth factor (VEGF), collagen type 1 alpha (COLA-1), and osteocalcin (OCN) gene 
expressions were evaluated. At early time points, IL-6, TNF-α, OPG, ALP-1, and VEGF 
expression increased with increasing Cu content, but at later time points the trend was reversed. 
RANKL and IL-17 expression did not occur until day 3, after which point increasing Cu amount 
corresponded to increasing gene expression. OCN expression showed consistent increase with 
increasing Cu for all three time points, as did COLA-1, until day 7 when all samples showed 
limited expression. 
a) 
 
b) 
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Figure 26. Gene marker expression of osteoblast cells after 1, 3, and 7 days of incubation. 
 
3.3.6.2 Co-BrC Gene Expression 
Hypoxia is known to induce the expression of HIF-1α, so the expression of HIF-1α in this study 
was conducted under normoxic and hypoxic conditions on scaffolds with varying concentrations 
of Co dopant. The expression of HIF-1α was significantly upregulated in hypoxic conditions on 
pure-BrC scaffolds compared to normoxic conditions, as was GLI2 expression (Figure 27a,b). 
Co dopant did not affect HIF-1α expression under normoxic conditions, though its expression 
was reduced in cells cultured on 0.25 Co-BrC scaffolds (Figure 27c). Similarly, no difference in 
GLI2 expression was observed with Co addition under normoxic conditions, though 1.0 Co-BrC 
scaffolds caused a decrease in GLI2 expression under hypoxia (Figure 27d).  
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Figure 27. HIF-1α and GLI2 expression under hypoxia and normoxia. 
 
3.4 Discussion 
Because of its compositional similarity to bone and its properties such as injectability, brushite 
cement is a feasible option for use in bone substitute applications. The limited osteoinductivity of 
most CaPs such as BrC can be enhanced with the use of growth factors or, as shown in this 
study, through the use of ionic substitutions. Specifically, this study examined the biological and 
physical effects of doping BrC scaffolds with Cu and Co. This was accomplished by 
synthesizing TCP powder via the solid-state method, and then mixing it with MCPM, PEG, and 
water to make the cement. Samples were seeded with OB or MG-63 osteosarcoma cells that were 
allowed to grow on pure and doped samples to quantify the difference in growth and gene 
expression with the addition of Cu or Co. The microstructure of the samples was analyzed using 
XRD and SEM, and the setting time and compression strength were also measured. 
  
a) 
 
b) 
 
c) 
 
d) 
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The precipitation of BrC occurs by mixing coarse and fine TCP powder with MCPM through the 
following chemical reaction [150]: 
Ca3(PO4)2 + Ca(H2PO4)2 × H2O + 7H2O → 4(CaHPO4 × 2H2O) 
The endothermic dissolution of MCPM, followed by the exothermic dissolution of ß-TCP, 
begins the precipitation reaction, which ends with an exothermic precipitation of BrC and an 
increase in the system pH. All samples were prepared in the same manner, with the amount of 
Cu or Co dopant being the only variable.  
3.4.1 Cu-BrC Discussion 
The ionic radius of Cu
2+
 is 73 pm, while the ionic radius of Ca
2+
 is 99 pm. The Cu ion is known 
to substitute for the Ca ion, which decreases the lattice size and increases stability. This increase 
in stability results in a decrease of dissolution rate and an increase in setting time. The phases of 
both the TCP powder and the brushite cement were characterized to highlight the phase change 
between the two. As anticipated, ß-TCP (JCPDS 09-0169) phases were present and dominant in 
the TCP powder. The transition between ß-TCP to α-TCP generally occurs around 1125 °C, so 
the calcination of TCP at 1050 °C did not induce the α phase [67]. The impact of Cu addition on 
the physical properties is clearly shown in the XRD data of the BrC. Within the doped samples, 
as the phase intensity of the DCPD increases, the phase intensity of ß-TCP decreases and a 
distinct bell curve in DCPD intensity can be seen from 0.25 to 1.0 Cu-BrC, with the peak at 0.5 
Cu-BrC. The dissolution rate of DCPD is greater than that of ß-TCP by a factor of 22, so the 
increase in DCPD phase intensity between 0.25 and 0.5 Cu-BrC may have contributed to the 
increase in setting time between the two [66]. This does not account for the extreme increase in 
setting time between 0.5 and 1.0 Cu-BrC, but as discussed earlier, the lattice shrinkage caused by 
the substitution of smaller Cu ions for the larger Ca ions also contributes to the increase in 
setting time. 
When conducting compressive strength testing, the 1.0 Cu-BrC samples were visibly 
deteriorated compared to the other samples. The setting time was measured last and gave some 
insight into this deterioration. As shown in Figure 23, the initial setting time of 1.0 Cu-BrC was 
14.67 minutes, and the final setting time was 51.17 minutes. Throughout the experiment, samples 
were transferred to the 37 °C environment to complete the setting time approximately 10 minutes 
after the cement was poured into the mold. After 1 hour, the samples were removed from the 
mold and transferred to PBS to further complete setting. However, this amount of time is barely 
more than the calculated final setting time of the 1.0 Cu-BrC samples. Because of this, the 
samples may not have had enough time to complete the setting reactions. However, based on the 
trend observed in the compression testing, one might expect the 1.0 Cu-BrC samples to have 
decreased strength compared to samples with less amounts of Cu. A general increase in setting 
time can be observed as the amount of Cu increases. However, there is a significant increase 
when 1.0 wt. % Cu is added. This signifies that Cu addition reduces the ability of the cement to 
set in a timely fashion, which is a significant consideration for injectable bone substitute 
materials.  
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Taking into account the significant increase in setting time of 1.0 Cu-BrC compared to the other 
samples, the results of the compressive testing are clear. A slight decrease in strength between 
0.5 and 1.0 Cu-TCP was expected, but because of the extended period of time required to 
complete the setting reaction for 1.0 Cu-TCP compared to the reduced amount of time that the 
samples were allowed to set, this more drastic decrease of compressive strength can also be 
expected. By observing the data, it can be postulated that the maximum compressive strength can 
be obtained by adding between 0–0.5 wt. % Cu to BrC, since the maximum observed 
compressive strength was at 0.25 wt. % Cu. Thus, Cu has the potential to increase compressive 
strength of BrC depending on dopant amount. 
The importance of the presence of Cu in the body as an essential trace element has been well 
documented, as has its toxicity on cellular and macro levels. Toxicity at a cellular level is often 
attributed to the breakdown of DNA strands by reactive oxygen species (ROS), which are 
created by Cu ions [133]. On a macro level, Cu toxicity can cause intestinal cramps, nausea, and 
decreased liver function [114]. In contrast, deficiency of Cu can lead to anemia and 
cardiomyopathy [111,114]. Cellular studies have shown an increase in VEGF secretion by 
mesenchymal stem cells with the addition of Cu to bioglass scaffolds and show no toxicity up to 
1 wt. % Cu addition [135]. Wu et al. corroborate these findings and further show an increase of 
ALP, OCN, and OPN secretion in a dose-dependent manner, though at higher Cu concentrations 
cell toxicity was observed [116]. Many other studies have indicated similar results regarding 
VEGF and other osteoinductive markers, and similar results were reported previously [19–21]. 
This study observed osteogenic gene expression similar to previous observations, with a few 
notable differences. 
Herein, a significant decrease in proliferation was observed with the addition of Cu dopant in a 
nearly linear dose-dependent manner at all kinetics. In an earlier study with ß-TCP scaffolds, 
relative OB proliferation was nearly equal for pure and 0.25 wt. % Cu scaffolds, whereas this 
study observed a significant decrease in relative proliferation at all concentrations of Cu. This 
highlights the difference in how cells react to various scaffolds, as all cellular procedures were 
constant between experiments. 
At the day 3 time point, relative proliferation of 1.0 Cu-BrC was just over 20%, and at day 7 it 
was just under 40%. A similar trend was observed for 0.25 and 0.5 Cu-BrC, which may explain 
why all gene expressions except IL-17, RANKL, and OCN were almost negligible at day 7. 
These three genes all had relatively small gene expression at day 1, whereas at later time points 
they had exponentially more expression. RANKL expression for all Cu-doped samples was 
greater than 200,000% relative expression.  
In a similar manner, IL-17 expression for 1.0 Cu-BrC at the latest kinetic was over 1,000,000% 
of relative IL-17 expression, and all doped samples were greater than 500,000%. IL-17 has been 
linked to increased expression of ALP, but that trend was not observed in this study [44]. Doped 
sample expression of ALP was increased at early time points but steadily decreased at later 
kinetics. At day 7, ALP expression for all doped samples was less than that of pure BrC. 
However, ALP is known as an early indicator of osteoblast differentiation and cellular activity, 
so lower expression at later kinetics when proliferation was decreased can be expected [129]. 
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IL-17 is also often associated with the production of other proinflammatory cytokines such as  
IL-6 and TNF-α and has been linked to the expression of RANKL [43]. It seems that IL-17 can 
enhance bone regeneration but also play a role in osteoclastogenesis and the expression of 
inflammatory cytokines [43–45]. There does seem to be a link between the increase in IL-17 
expression and the increase in RANKL expression at later kinetics, though there may be other 
factors involved.  
The expression of IL-6 did not follow the pattern of IL-17 expression; IL-6 expression increased 
in a dose-dependent manner at the first time point, but expression slowly decreased until at the 
latest kinetic, and almost no IL-6 expression was observed with doped samples, compared to 
increased expression of IL-6 by the pure BrC at that time. IL-6 has been linked to osteoarthritis, 
osteoclastogenesis, and ECM mineralization and is a proinflammatory cytokine [38,39,41]. Cu 
may inhibit the expression of IL-6 at later kinetics, as the increase in expression of other 
osteoclastogenesis markers and proinflammatory cytokines was observed. 
Similar to IL-6, TNF-α is a proinflammatory cytokine and is linked to osteoclastogenesis and 
inflammatory bone diseases [46,151]. It also inhibits expression of COLA-1 and OCN, and 
reduces the mineralization of the matrix [46,47]. TNF-α expression increased in a dose-
dependent manner at the earliest time point, after which expression decreased for all doped 
samples compared to pure BrC, which suggests that at later kinetics Cu dopant had a therapeutic 
effect on reduction of this inflammatory cytokine.  
To regulate osteoclastogenesis, OPG acts as a decoy receptor to RANKL, which binds to OPG 
instead of receptor activator of nuclear factor κ-ß (RANK) [19,24]. This inhibits the formation of 
osteoclasts and thus reduces bone resorption. Mice studies have shown that an overabundance of 
OPG expression results in osteopetrosis, whereas osteoporosis occurs with a lack of OPG [25]. In 
addition, RANKL and OPG expression have an inverse relationship, so increases in expression 
of RANKL are linked to decreases in expression of OPG [19]. There is clearly such an inverse 
relationship present in the data gathered in this experiment, as at later kinetics when RANKL 
expression significantly increased, relative OPG expression decreased. At the first time point, 
Cu-doped samples had a much greater OPG expression compared to pure BrC, and the same 
trend was present to a lesser degree at the second time point. The OPG expression at the final 
kinetic for all doped samples was significantly reduced compared to pure BrC at the final time 
point. This suggests a trend towards favorable conditions for osteoclastogenesis because of the 
increased IL-17 and RANKL expression combined with this decrease in OPG expression.  
The metabolic activity of bone can be indicated by the gene OCN, the expression of which also 
indicates bone formation [49]. OCN is secreted solely by osteoblasts and bonds well with the 
hydroxyapatite in bone, helping to ensure mineralization [50,51]. It is secreted once the 
osteoblasts are mature, which is why an increase in OCN expression is seen at later kinetics. The 
highest levels of OCN expressed by Cu-doped samples occurred at day 3, whereas the highest 
expression of OCN for the undoped samples occurred at day 7. This could indicate that 
osteoblast cells cultured in the presence of Cu mature more rapidly than those cultured on pure 
BrC scaffolds. The increased expression of OCN at later kinetics on doped samples compared to 
the pure sample suggests that the presence of Cu does enhance osteoblast expression of OCN.  
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While OCN is one of the main noncollagenous proteins found in bone, collagen is by far the 
most abundant protein. Combined with COLA-2, COLA-1 produces the fibril-forming type 1 
collagen, which is essential to the mineralization of the bone matrix, and it is also considered a 
marker of osteoblast differentiation and ALP production [48]. At early kinetics, a large increase 
was seen in COLA-1 production by doped samples in a dose-dependent manner, though at the 
final time point all expression of COLA-1 decreased. This, combined with a low expression of 
TNF-α at later kinetics and a high expression of OCN at early kinetics, suggests favorable bone 
matrix mineralization trends with the presence of Cu. 
Angiogenesis and osteogenesis are closely related processes, and both are essential for healthy 
bone growth. The vascularization of bone ensures that blood can flow and provide oxygen to the 
bone. VEGF is an indicator of blood vessel growth and the ossification of bone and is mostly 
expressed during mineralization [33,34,36]. Thus, the increase in expression of VEGF at early 
time points for Cu-doped samples may indicate earlier mineralization compared to pure samples 
and again suggest a more rapid maturation of osteoblasts cultured in the presence of Cu. 
Reduction of VEGF expression at the latest kinetic for Cu-doped samples compared to pure BrC 
could occur because of the later maturation of osteoblast cells cultured on the pure BrC samples. 
3.4.2 Co-BrC Discussion 
The Co ionic radius is 0.074 nm, and it substitutes in the Ca
2+
 site in CaP ceramics. As a result of 
its smaller size compared to Ca
2+
 (0.099 nm), the substitution is accompanied by lattice 
shrinkage and enhances its stability, which, in turn, results in a slower dissolution rate. The XRD 
results herein show that the ß-TCP/DCPD (JCPDS No. 09-0077) ratio (calculated from the 
height of peaks with 100% intensity for ß-TCP and DCPD at 2Ɵ = 31.1° and 21°, respectively) is 
increasing with the addition of dopants from 1.10 to 1.56, 1.68, and 2.02 for BrC, 0.25 Co-BrC, 
0.5 Co-BrC, and 1.0 Co-BrC, respectively [106]. These results prove that the stability of TCP 
decreases the dissolution rate and, as a result, decreases the BrC formation.  
Dissolution of precursors or precipitation of DCPD resulted in a prolonged setting reaction and 
in enhanced compressive strength in the Si-doped BrC system [87] and in the Cu-doped BrC 
system reported earlier. In this Co-BrC system, the setting time decreased slightly for low dopant 
amounts of Co, though at higher dopant amounts there was an increase in both initial and final 
setting times. This most likely occurs because of the increase in ß-TCP dissolution rate due to the 
formation of DCPD and the inhibited DCPD precipitation due to the presence of ß-TCP. 
In this study, the Co dopants were added to TCP precursors prior to calcination. An alternative 
method for adding Co dopants that was attempted was to add corresponding CoCl2 salt dopant 
amounts to the PEG-H2O mixture, which was then mixed with pure powder. The samples were 
formed, but while the setting reactions were completed in PBS solution, the dopant began to 
leach out of the samples as shown in Figure 28. Therefore it was determined that, for all samples, 
dopant should be added to the TCP precursors. 
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Figure 28. CoCl2 leached out of samples. 
 
To evaluate the effects of Co and its concentration in BrC on osteosarcoma cell proliferation, the 
in vitro interaction between the cells and samples was investigated under both normoxic and 
hypoxic conditions. Co is a vital element in DNA synthesis, and its role as an antibacterial 
element is reported in reference [152]. Nevertheless, high concentrations of Co can cause 
toxicity in living cells [153]. Current results show that although there was a modest (20%) 
increase in MG-63 cell growth on pure BrC under hypoxia compared with normoxia, this 
increase did not reach statistical signiﬁcance. Furthermore, the presence of Co at different 
concentrations did not affect MG-63 cell growth on BrC under normoxic or hypoxic conditions. 
These results are interesting because a previous study found that adding cobalt ions directly to 
the cell culture medium reduced the viability of osteoblasts and osteosarcoma cells in 2D culture 
[154]. However, the data shown in this study represent the 3D culture condition using a scaffold. 
Therefore, a comprehensive analysis of the differences between 2D and 3D cell culture models 
would aid in understanding the effects of Co and other additives to 3D cell culture systems. On 
the other hand, Zhang et al. found that the addition of Co to TCP at concentrations of 2 and 5 
mol. % does not result in cytotoxicity in human bone marrow mesenchymal stem cells [142]. 
This proves that although the Co shows toxicity to some cell lines, its interaction with different 
cell lines in various systems should be evaluated [142].  
Because hypoxia induces the expression of HIF-1α, this study examined HIF-1α expression by 
qPCR in MG-63 cells cultured on Co-BrC. Consistent with previous studies [141,142], MG-63 
cells cultured on pure-BrC disks under hypoxic conditions significantly upregulated the 
expression of HIF-1α (p = 0.0079; Figure 27) [155]. The transcription factor GLI2 has been 
shown to be induced under hypoxic conditions. Furthermore, GLI2 has been shown to be 
upregulated in osteosarcoma tumor samples from patients, correlated with a poor prognosis, and 
its genetic inhibition results in a reduction in cell growth and survival [156–159]. Therefore, the 
GLI2 expression in the BrC model system was examined. Consistent with previous studies, the 
expression of GLI2 is induced in MG-63 cells cultured under hypoxic conditions on pure BrC  
(p = 0.0002; Figure 27).  
Next the effect of Co on HIF-1α and GLI2 expression was examined. It was found that the 
presence of Co ions did not affect HIF-1α expression under normoxic conditions. Under hypoxic 
conditions, only the low dose of Co (0.25 wt. %) statistically reduced HIF-1α expression. 
Similarly, the addition of Co had no effect on GLI2 expression under normoxia. Nevertheless, 
under hypoxic conditions, the Co-BrC (1 wt. %) signiﬁcantly reduced hypoxia-induced GLI2 
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expression (Figure 27). Taken together, these data suggest that in 3D cultures using Co-BrC, the 
addition of Co may reduce hypoxia-induced modulation of HIF-1α and GLI2 expression. Both 
hypoxia [145,160,161] and GLI2 [118,162] have been shown to induce inﬂammatory cytokine 
genes. Therefore, Co may indirectly reduce inﬂammation by regulating the expression of two 
proteins that regulate inﬂammation. Inﬂammation has been shown to promote tumorigenesis 
[163], and it facilitates osteosarcoma cell growth [164]; therefore, this 3D Co-BrC model system 
may provide therapeutic beneﬁt for osteosarcoma by reducing hypoxia-induced gene expression. 
3.5 Conclusion 
In this work, the effect of Cu and Co dopants on the physical and biological characteristics of 
BrC was studied. The addition of up to 0.25 wt. % Cu was found to enhance the compressive 
strength of BrC samples. DCPD precipitation was clearly inhibited with the addition of Cu and 
Co, and as a result the setting time increased with increasing Cu and Co content. Cu also reduced 
the expression of inflammatory markers and enhanced the expression of osteogenic markers such 
as VEGF, while Co inhibited the expression of proinflammatory HIF-1α and GLI2 under 
hypoxia. No cytotoxicity was observed for MG-63 osteosarcoma cells under hypoxia or 
normoxia with the addition of Co dopant, though reduced proliferation was observed for OB 
cells with all amounts of Cu dopant. 
 
CHAPTER 4   SUMMARY AND FUTURE WORK 
4.1 Summary 
Because of the prominence of diseases such as osteoporosis and arthritis, which affect people 
worldwide and even in outer space, the biology, engineering, materials science, and medical 
communities are actively studying various biomaterials that may be utilized as bone substitute 
materials. Calcium phosphates are among the materials studied and are promising because of 
their compositional similarity to bone, their resorption behavior, and their ability to be used in 
different forms. Calcium phosphates are naturally osteoconductive, but they lack 
osteoinductivity, or the ability to induce de novo bone formation. Because of this, various 
methods are utilized to stimulate bone formation in conjunction with these CaP materials, 
including incorporating growth factors and trace amounts of essential elements. By integrating 
metal ions into the CaP materials, the physical and mechanical properties of the materials can 
also be modified.  
In this study, trace amounts of Cu and Co were incorporated into tricalcium phosphate and 
brushite cement calcium phosphate materials in an effort to quantify the biological and physical 
impact of the incorporation of these materials. An excess of these metals can be toxic to the body 
or have an adverse effect on the physical and mechanical properties, so various trace amounts 
were utilized.  
As anticipated, the incorporation of Cu and Co into TCP and BrC caused changes in the 
microstructure and phase diagrams of the materials. The density, setting time, and compressive 
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strength were also altered. The compressive strength of Cu-BrC increased with 0.25 Cu dopant 
but decreased with increasing amounts of Cu. The initial and final setting times of Cu- and Co-
doped BrC increased with increasing amounts of dopant, and a significant increase in setting 
time was observed between 0.5 and 1.0 Cu-BrC. Decreasing amounts of DCPD precipitation 
were observed in the XRD data for BrC with incorporation of dopants. The open porosity of TCP 
samples was impacted less by sintering temperature when Cu dopants were present. In addition, 
the α-TCP phase was inhibited from forming by the incorporation of Cu into TCP samples. 
Biologically, the incorporation of Cu and Co into samples resulted in both positive and negative 
osteoinductive impacts. The expression of gene markers is commonly used to quantify 
osteoinduction, and several of those markers were studied herein. In the two Cu studies, IL-17, 
IL-6, TNF-α, RANKL, OPG, ALP-1, VEGF, COLA-1, and OCN expressions were observed.  
IL-17, IL-6, and TNF-α are proinflammatory gene markers, though they have beneficial roles as 
well. IL-17 expression increased in both studies, though IL-6 and TNF-α expression decreased at 
later kinetics, suggesting that Cu plays a therapeutic role in reduction of inflammation. The early 
increase in expression of ALP-1 and VEGF, and the later increase of expression in OCN 
indicates that Cu plays a beneficial role in osteoinduction in osteoblasts for BrC and TCP.  
The incorporation of Co into BrC samples reduced the expression of HIF-1α and GLI2 under 
hypoxic conditions, which again signifies that Co has an anti-inflammatory therapeutic effect on 
MG-63 osteosarcoma cells. In addition, no cytotoxicity was observed with doped samples 
compared to MG-63 proliferation on pure-BrC samples. These positive effects of Cu and Co on 
the osteoinductive markers and the reduction in expression of proinflammatory markers suggest 
that further investigation and laboratory testing should be conducted on these two trace elements.  
4.2 Future Work 
The author recommends continued research on BrC and TCP calcium phosphates as bone 
substitute materials. The compressive strength of Cu-TCP and Co-BrC were not considered in 
this study, but should be investigated. In addition, therapeutic effects were observed for all 
dopant amounts of Co, so increased wt. % of Co dopant may be considered. The surface 
morphologies should be further considered for the Cu-doped materials as well.  
Co-BrC had therapeutic effects on reducing HIF-1α and GLI2 expression, but no qPCR was 
conducted to quantify the effects of Co addition on other osteoinductive markers. Further 
research should be conducted in considering those markers. In addition, Co-TCP was not 
considered and should be investigated as a bone substitute material. 
In vitro studies were conducted in the research presented herein, but further work should include 
in vivo studies using rabbits and rats in a laboratory setting. Histological results offer further 
insight into the effects of dopants on tissue and a more complete picture of the ramifications of 
utilizing potentially toxic metals. Because of the promising initial results presented herein, in 
vivo studies should be pursued. 
Finally, the incorporation of other trace elements, such as Chromium (Cr), should continue to be 
studied, as should alternative sample fabrication methods. Work has begun to control the 
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porosity of TCP samples through the use of substances such as naphthalene, which can be 
incorporated in controlled particle sizes and then evaporated using low-heat furnaces. The 
utilization of such porous samples, and the sequential incorporation of dopants into the samples, 
could further enhance the osteoinductive capacity of TCP and increase its ability to bond with 
bone. 
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